Renal Anemia | Access & Reimbursement | US examines the market access factors that influence the success of therapies for the treatment of renal anemia. The series is based on primary research data with U.S. nephrologists and MCO pharmacy and medical directors. This research explores how payers and physicians interact and how reimbursement decisions impact the prescribing and uptake of specific therapies at the brand level.

Table of contents

  • Renal Anemia - Access & Reimbursement - Detailed, Expanded Analysis (US)

Author(s): Jihan Khan, PhD

Jihan Khan, Ph.D., is a director in the oncology team at DRG. Dr. Khan manages a team of analysts who conduct extensive primary and secondary market research on several oncology indications across the major pharmaceutical markets. She also provides sales and client support across DRG oncology products.


Previously, Dr. Khan was a principal analyst on the cardiometabolic team at DRG. Her specialties were the type 2 diabetes and renal disorders markets. Dr. Khan provided forecasts of these pharmaceutical markets by evaluating the agents in development and the changing clinical behaviors and conducting primary research with payers and physicians. Prior to joining DRG, she worked as a knowledge specialist in a company where she conducted in-depth research on products and processes for commercialization. She obtained her Ph.D. in organic chemistry from Brandeis University and was a postdoctoral fellow at Brigham and Women’s Hospital and Harvard Medical School.

Related Reports

Renal Anemia - Current Treatment - Detailed, Expanded Analysis (US)

Renal anemia is a common complication of chronic kidney disease (CKD). Although treatment options exist, physicians, patients, and healthcare systems have concerns about their limitations. Delivery...

View Details

Renal Anemia - Landscape & Forecast - Disease Landscape & Forecast

View Details